Let our AI Intelligence Engine carry the broad search, so your team can commit where the evidence is strongest.
The search for a cure — capsid, target, trial design, treatment pathway — burns the most resources at the broadest part of the funnel, where the most candidates fail. Atlas Bio's platform takes that broad search and runs it through a calibrated, audit-traceable engine. Your team owns the high-confidence shortlist — the candidates the platform has named, ranked, and justified — not the whole space.
Broad search, audit-traceable
- Evidence aggregation across heterogeneous sources
- Calibrated ranking with credible intervals
- Translation-trap detection (the LY6A pattern, the mouse-to-NHP gap)
- Per-candidate failure-mode flagging
- Designed to learn from partner data once partner programs begin
Final commitment, expensive verification
- Wet-lab execution on shortlisted candidates
- NHP cohort design and biodistribution studies
- Clinical trial commitment and operational rollout
- Final go / no-go decisions under SME judgment
- Domain-specific interpretation of platform outputs
The leverage shift. The work the platform handles is the volume work — broad, repetitive, evidence-aggregating, low cost per candidate. The work your team handles is the irreplaceable judgment work — expensive per candidate, but now applied where it counts. The funnel doesn't replace your team. It changes the leverage ratio.
Straight answers on AI in drug discovery
Plain-language answers with sources, written by Atlas Bio — on evidence standards for AI biology, AAV capsid design, safety signals and real-world evidence.
Need a defensible answer in a hard population?
Briefings are 30 minutes. Bring a regimen, an indication, or a capsid spec; we walk through how the framework would model it. Verified clinicians and sponsors unlock the manuscript bundle.
Contact Us →